RATIONALE: Deliberate self-poisoning (DSP), the most common form of deliberate self-harm, is closely associated with suicide. Identifying risk factors of DSP is necessary for implementing prevention strategies. OBJECTIVES: This study aimed to evaluate the relationship between benzodiazepine (BZD) treatment in psychiatric outpatients and DSP cases at emergency departments (EDs). METHODS: We performed a retrospective nested case-control study of psychiatric patients receiving BZD therapy to evaluate the relationship between BZD use and the diagnosis of DSP at EDs using data from the nationwide Taiwan National Health Insurance Research Database. RESULTS: Regression analysis yielded an odds ratio (OR) and 95 % confidence interval (95 % CI) indicating that the use of BZDs in psychiatric outpatients was significantly associated with DSP cases at EDs (OR = 4.46, 95 % CI = 3.59-5.53). Having a history of DSP, sleep disorders, anxiety disorders, schizophrenia, depression, or bipolar disorder was associated with a DSP diagnosis at EDs (OR = 13.27, 95 % CI = 8.28-21.29; OR = 5.04, 95 % CI = 4.25-5.98; OR = 3.95, 95 % CI = 3.32-4.70; OR = 7.80, 95 % CI = 5.28-11.52; OR = 15.20, 95 % CI = 12.22-18.91; and OR = 18.48, 95 % CI = 10.13-33.7, respectively). After adjusting for potential confounders, BZD use remained significantly associated with a subsequent DSP diagnosis (adjusted OR = 2.47, 95 % CI = 1.93-3.17). Patients taking higher average cumulative BZD doses were at greater risk of DSP. CONCLUSION: Vigilant evaluation of the psychiatric status of patients prescribed with BZD therapy is critical for the prevention of DSP events at EDs.
RATIONALE: Deliberate self-poisoning (DSP), the most common form of deliberate self-harm, is closely associated with suicide. Identifying risk factors of DSP is necessary for implementing prevention strategies. OBJECTIVES: This study aimed to evaluate the relationship between benzodiazepine (BZD) treatment in psychiatric outpatients and DSP cases at emergency departments (EDs). METHODS: We performed a retrospective nested case-control study of psychiatricpatients receiving BZD therapy to evaluate the relationship between BZD use and the diagnosis of DSP at EDs using data from the nationwide Taiwan National Health Insurance Research Database. RESULTS: Regression analysis yielded an odds ratio (OR) and 95 % confidence interval (95 % CI) indicating that the use of BZDs in psychiatric outpatients was significantly associated with DSP cases at EDs (OR = 4.46, 95 % CI = 3.59-5.53). Having a history of DSP, sleep disorders, anxiety disorders, schizophrenia, depression, or bipolar disorder was associated with a DSP diagnosis at EDs (OR = 13.27, 95 % CI = 8.28-21.29; OR = 5.04, 95 % CI = 4.25-5.98; OR = 3.95, 95 % CI = 3.32-4.70; OR = 7.80, 95 % CI = 5.28-11.52; OR = 15.20, 95 % CI = 12.22-18.91; and OR = 18.48, 95 % CI = 10.13-33.7, respectively). After adjusting for potential confounders, BZD use remained significantly associated with a subsequent DSP diagnosis (adjusted OR = 2.47, 95 % CI = 1.93-3.17). Patients taking higher average cumulative BZD doses were at greater risk of DSP. CONCLUSION: Vigilant evaluation of the psychiatric status of patients prescribed with BZD therapy is critical for the prevention of DSP events at EDs.
Authors: F-J Baylé; O Blanc; I De Chazeron; J Lesturgeon; C Lançon; H Caci; R-P Garay; P-M Llorca Journal: Encephale Date: 2010-10-12 Impact factor: 1.291
Authors: Keith Hawton; Helen Bergen; Deborah Casey; Sue Simkin; Ben Palmer; Jayne Cooper; Nav Kapur; Judith Horrocks; Allan House; Rachael Lilley; Rachael Noble; David Owens Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2007-05-21 Impact factor: 4.328
Authors: Ivan J Perry; Paul Corcoran; Anthony P Fitzgerald; Helen S Keeley; Udo Reulbach; Ella Arensman Journal: PLoS One Date: 2012-02-20 Impact factor: 3.240
Authors: Ariel Berger; John Edelsberg; Kafi N Sanders; Jose Ma J Alvir; Marko A Mychaskiw; Gerry Oster Journal: BMC Psychiatry Date: 2012-08-02 Impact factor: 3.630
Authors: William V Bobo; Noreen A Reilly-Harrington; Terence A Ketter; Benjamin D Brody; Gustavo Kinrys; David E Kemp; Richard C Shelton; Susan L McElroy; Louisa G Sylvia; James H Kocsis; Melvin G McInnis; Edward S Friedman; Vivek Singh; Mauricio Tohen; Charles L Bowden; Thilo Deckersbach; Joseph R Calabrese; Michael E Thase; Andrew A Nierenberg; Dustin J Rabideau; David A Schoenfeld; Stephen V Faraone; Masoud Kamali Journal: J Clin Psychopharmacol Date: 2015-02 Impact factor: 3.153